UAE approves new oral obesity treatment

The UAE has become the second country in the world to approve Foundayo (orforglipron), a new oral treatment for chronic weight management.

The Emirates Drug Establishment has given the green light to the medication, developed by global pharmaceutical company Eli Lilly.

The once-daily pill is designed to support weight reduction without the need for injections, marking a significant shift in how obesity can be treated and improving the overall patient experience.

Officials say the approval reflects the UAE’s commitment to fast-tracking access to cutting-edge medicines and strengthening a pharmaceutical sector built on innovation, efficiency and sustainability.

Orforglipron works by regulating appetite and reducing excessive food intake. It is intended for long-term use as part of a broader programme that includes lifestyle changes and overall health improvement.

Director-General of the Emirates Drug Establishment, Dr. Fatima Al Kaabi, described the approval as a major milestone, highlighting the country’s focus on adopting the latest treatments, particularly for people living with obesity.

She added that the authority will continue working with global partners to ensure high-quality therapies are made available quickly, while supporting prevention efforts and safeguarding public health.

The approval follows clinical trials showing strong results, with patients on the highest dose losing an average of more than 12 per cent of their body weight when combined with lifestyle guidance.

Experts note that tackling obesity remains a priority, given its link to more than 200 health conditions, including type 2 diabetes, hypertension and several forms of cancer.

Eli Lilly says the new treatment offers an additional option for patients managing obesity and will soon be available in the UAE.

The medication is expected to reach eligible patients starting in May 2026.

EDE continues to reinforce its leadership position in the pharmaceutical sector with the approval of the innovative oral therapy Orforglipron, making the UAE the second country in the world to register it. pic.twitter.com/zGoK7oYUw6

— Emirates Drug Establishment مؤسسة الإمارات للدواء (@EDE_UAE) April 3, 2026